Research Analysts Set Expectations for BrainsWay Q1 Earnings

BrainsWay Ltd. (NASDAQ:BWAY) – Stock analysts at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of BrainsWay in a research report issued to clients and investors on Tuesday, May 27th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.04 per share for the quarter, up from their prior estimate of $0.03. HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for BrainsWay’s current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for BrainsWay’s Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.09 EPS and FY2026 earnings at $0.27 EPS.

BrainsWay (NASDAQ:BWAY) last announced its quarterly earnings results on Tuesday, May 13th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. The company had revenue of $11.54 million during the quarter, compared to analyst estimates of $11.45 million.

BrainsWay Stock Performance

Shares of BWAY stock opened at $10.43 on Wednesday. BrainsWay has a 1 year low of $5.67 and a 1 year high of $11.79. The stock has a fifty day moving average of $9.22 and a two-hundred day moving average of $9.72. The firm has a market capitalization of $196.83 million, a PE ratio of 104.31 and a beta of 1.25.

Institutional Trading of BrainsWay

Several institutional investors have recently modified their holdings of the company. Two Sigma Investments LP lifted its holdings in shares of BrainsWay by 2.0% in the fourth quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock valued at $875,000 after buying an additional 1,786 shares during the period. Rhumbline Advisers lifted its holdings in shares of BrainsWay by 10.8% in the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock valued at $207,000 after buying an additional 2,144 shares during the period. Cubist Systematic Strategies LLC lifted its holdings in shares of BrainsWay by 14.6% in the fourth quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock valued at $181,000 after buying an additional 2,446 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of BrainsWay in the fourth quarter valued at $44,000. Finally, NewEdge Advisors LLC lifted its holdings in shares of BrainsWay by 61.5% in the first quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock valued at $188,000 after buying an additional 7,549 shares during the period. Institutional investors and hedge funds own 30.11% of the company’s stock.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.